Mereo BioPharma Group plc

NASDAQ:MREO

Biotechnology

Healthcare
$0.32 +9.69%

+$0.03 today

Market cap
$51.08M
Beta
0.28
P/E (TTM)
-1.4
EPS (TTM)
-$0.22
52W Low $0.20High $3.05

Volume 1.26M

Average 3.36M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$30.97M

FY 2025 · Annual

Investing Cash Flow

-$20,000.00

FY 2025 · Annual

Financing Cash Flow

$327,000.00

FY 2025 · Annual

-99.3% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income19.22M(42.22M)(29.47M)(43.25M)(41.88M)
Depreciation & Amortization866.47K889K1.06M1.09M622K
Deferred Income Tax00000
Stock-Based Compensation4.46M4.77M4.92M7.39M7.6M
Change in Working Capital(2.49M)(2.35M)(1.59M)(369K)(3.21M)
Accounts Receivables(794.94K)(3.47M)456K(1.65M)1.4M
Inventory00000
Accounts Payables0617K(1.26M)146K(1.38M)
Other Working Capital(1.7M)498K(786K)1.13M(3.23M)
Other Non-Cash Items(29.12M)(9.91M)3.94M2.31M5.9M
Operating Cash Flow(7.07M)(48.82M)(21.13M)(32.83M)(30.97M)
Capital Expenditures(722.06K)(13K)(419K)(699K)(20K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities153.86K2M(419K)00
Investing Cash Flow(568.2K)1.99M(419K)(699K)(20K)
Debt Repayment(933.95K)0(3.19M)00
Common Stock Issued105.99M011.61M47M327.76K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(253.73K)200K24K(853K)(764)
Financing Cash Flow104.8M200K7.97M46.15M327K
Effect of Forex Changes(1.57M)(12.58M)2.82M(233K)1.93M
Net Change in Cash95.59M(59.22M)(10.76M)12.38M(28.81M)
Free Cash Flow(7.79M)(48.83M)(21.55M)(33.53M)(30.99M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$41.9M
+ D&A$622.0K
+ Stock-Based Comp$7.6M
+ Deferred Tax$0
- Working Capital-$3.2M
+ Other Non-Cash$5.9M
= Operating Cash Flow-$31.0M
- Capex-$20.0K
= Free Cash Flow-$31.0M

Analysis

FY2025 free cash flow is -$31.0M. FCF conversion is 74.0% of net income. Operating cash flow was -$31.0M, with capex of -$20.0K. The largest bridge item is Stock-Based Comp at $7.6M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportAug 19, 2026
SC 13G/ASC 13G/A filingAug 14, 2026
10-QQuarterly reportAug 11, 2026
8-KCurrent reportAug 11, 2026
8-KCurrent reportAug 11, 2026

Does MREO generate free cash flow?

Mereo BioPharma Group plc (MREO) generated -$30.99M of free cash flow in fiscal 2025.

How much operating cash flow does MREO produce?

Operating cash flow was -$30.97M, before capital expenditures of $20,000.00.